Clinical Trial

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-02-10; most recent amendment 2026-04-07.
Status change: Recruiting → Active, Not Recruiting 2024-01-24
Status change: Not Yet Recruiting → Recruiting 2023-01-03
Trial Details
NCT Number NCT05249114
Lead Sponsor Providence Health & Services
Collaborators: Exelixis, Advanced Accelerator Applications
Conditions Neuroendocrine Tumors
Enrollment 6 participants
Start Date 2022-12-28
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-13